HPRA (Health Products Regulatory Authority)

Who regulates medicines in Ireland?

In one sentence

The HPRA is Ireland's regulator of medicines, medical devices and other health products, and its competent authority for pharmacovigilance.

A small agency with a large European Union (EU) desk: it licenses and inspects at home, sits on the European Medicines Agency (EMA) safety committee for Ireland, and assesses new medicines for the whole EU as rapporteur.

Where it sits

MinisterMinister for Health, who appoints the Authority
Statutory bodyHealth Products Regulatory Authority
Runs it day to dayThe Chief Executive and the Management Committee
PharmacovigilanceHuman medicines vigilance, feeding EudraVigilanceSuspected reactions land here

Think of it like this

Think of a harbourmaster in a small port on a busy coast. Every ship that lands is checked locally, but the tide tables and the storm warnings come from a shared service the harbourmaster helps to run.

Key insights

Three dates, one agencyA small agency with a big EU deskCompanies send 85 percent of the reportsIreland’s own rules on top

Established on 1 January 1996 as the Irish Medicines Board, made the pharmacovigilance authority under the EU’s 2012 rules, renamed the HPRA on 1 July 2014 as its remit grew. Chapter 1 tells the story.

In 2024 the HPRA was rapporteur or co-rapporteur for 13 new medicines in the EU’s centralised procedure, coordinated 72 scientific advice requests and monitored safety signals for 70 centrally authorised medicines at the EMA’s safety committee.

Of the 7,885 suspected reaction reports received in 2024, 85.5 percent came from marketing authorisation holders, 7 percent from the public and 7 percent from health professionals. Chapter 2 sets the clocks for each.

Safety letters to doctors need the HPRA’s national approval and carry its identifier on page one; educational materials from a risk management plan need its approval three months before launch. Chapter 3 lists what Ireland adds.

Jump to: 1 Three moments 2 Your report, their clock 3 What Ireland adds to the EU rules 4 Test yourself

Chapter 1

Which three moments made the HPRA what it is?

Pick a year. Each widened what the agency does.

1996A board of its own2012The EU rewrites the rules2014A new name for a wider remit

A board of its own

The Irish Medicines Board Act 1995 created a standalone board, and a ministerial order fixed its first day: 1 January 1996. The Act gave it the licensing of medicines, the EU competent authority powers, clinical trials, and a service for gathering and assessing safety information.

The shape set then still holds: a board of nine appointed by the Minister for Health, and a Chief Executive appointed by the board with the Minister’s consent.

What it left behind: an agency funded mostly by the fees it charges, not by the exchequer.

The EU rewrites the rules

The 2012 overhaul of EU pharmacovigilance reached Ireland as S.I. No. 272 of 2012. It made the board operate a pharmacovigilance system of its own, encourage and facilitate reporting by patients and professionals, run a web portal, and pass every report to EudraVigilance: serious ones within 15 days, the rest within 90.

The same year the EMA’s safety committee was created, and the HPRA took Ireland’s seat on it. Today it monitors the signals of 70 centrally authorised medicines there.

What it left behind: the clocks in chapter 2, and a seat at the table where EU safety decisions start.

A new name for a wider remit

On 1 July 2014 the Irish Medicines Board became the Health Products Regulatory Authority, under section 36 of the Health (Pricing and Supply of Medical Goods) Act 2013 and its commencement order. The board became “the Authority”; the Act of 1995 stayed the legal base.

The name says what the remit had become: medicines, medical devices, blood, human tissues and cells, organs for transplantation, controlled substances, cosmetics, and the use of animals for scientific purposes.

What it left behind: one regulator for the whole cupboard, from a vaccine to a contact lens to a lipstick.

Chapter 2

Your report, their clock

A case has reached your company. S.I. No. 272 of 2012 sets the deadline for a suspected adverse drug reaction (ADR) with two questions: is it serious, and was it in the EU? Pick a cell.

In the EUOutside the EUSeriousSerious, in the EUSerious, outside the EUNot seriousNot serious, in the EUNot serious, outside the EU

Or the case came another way: a patient or doctor reported it to the HPRA or you found it in a journal the EMA already monitors

Every serious suspected reaction goes electronically to EudraVigilance no later than 15 days, with follow-up information collected and sent as updates. S.I. 272/2012, regulation 32(1)(c) and (d)

A non-serious suspected reaction in the Union goes to EudraVigilance no later than 90 days. S.I. 272/2012, regulation 32(1)(c); Directive 2001/83/EC, Article 107(3)

A non-serious reaction outside the Union is not on the 15 or 90 day list. It stays in your pharmacovigilance system, which must be equivalent to the authority’s own. Directive 2001/83/EC, Article 107(3); S.I. 272/2012, regulation 31

Reporting is encouraged, not compulsory. The HPRA must record the case, obtain verifiable data, involve the reporter in follow-up, and send it to EudraVigilance within 15 days if serious, 90 if not. S.I. 272/2012, regulations 30 and 33

For substances on the EMA’s list of monitored publications you need not report what the listed journals contain; you must still monitor and report everything else in the literature. S.I. 272/2012, regulation 32(3)

Encourage and facilitate the reporting of adverse reactions to medicinal products by patients, doctors, pharmacists and other healthcare professionals.
What the authority itself must do, S.I. No. 272 of 2012, regulation 30(c)

The encouragement works modestly: of the 7,885 reports received in 2024, 85.5 percent came from companies. Among the reports sent directly, patients and carers were the largest group at 52 percent, then pharmacists at 18, doctors at 14 and nurses at 9. Black triangle medicines made up 9.2 percent of everything received.

Chapter 3

What does Ireland add to the EU rules?

The directive sets the floor. Five places where the HPRA built its own layer on top.

	The EU rule	Ireland’s own layer
A report from the public	Member States encourage patients and professionals to report	The HPRA must record it, obtain verifiable data and involve the reporter in the follow-up, then forward it within 15 or 90 days
Letters to doctors	Direct healthcare professional communications under the EU guidelines	National approval by the HPRA, with its identifier at the top of page one and no promotional content
Educational materials	Part of the risk management plan	Materials in an EU risk management plan need HPRA approval, submitted three months before launch
The company’s people	A qualified person for pharmacovigilance, permanently and continuously	The same person, who must reside and operate in the European Economic Area
Who approves	The European Commission, on the EMA’s opinion, for centralised medicines	The HPRA licenses nationally, and in 2024 was rapporteur or co-rapporteur for 13 centralised applications

Show the legal references

Reports: Directive 2001/83/EC, Article 102(a); S.I. 272/2012, regulations 30(c) and 33.
Letters and materials: the HPRA’s national pharmacovigilance requirements for marketing authorisation holders (guides on direct healthcare professional communications, 18 September 2025, and on educational tools and materials, 17 June 2014).
People: Directive 2001/83/EC, Article 104(3)(a); S.I. 272/2012, regulation 31(b).
Approval: Regulation (EC) No 726/2004, Article 10(1); Irish Medicines Board Act 1995, section 4(1)(a); HPRA Annual Report 2024.

Same Europe, one more signature: in Ireland the safety letter and the risk materials pass the HPRA’s desk before they reach a doctor.

The facts, in one place

What it is	A statutory body under the Irish Medicines Board Act 1995, governed by an Authority of a chairperson and eight members appointed by the Minister for Health; the Chief Executive runs it day to day.
Since	1 January 1996 as the Irish Medicines Board; the Health Products Regulatory Authority since 1 July 2014.
Seat	Kevin O’Malley House, Earlsfort Terrace, Dublin 2.
Money and people	Income of €43.0 million in 2024, €35.9 million of it fees and €5.7 million from the Department of Health; an average of 406 staff.
2024 in numbers	462 new human medicines authorised, 82 clinical trial authorisations, 7,885 suspected reaction reports, 83 manufacturing inspections.
Pharmacovigilance	The competent authority for Ireland, with Ireland’s seat on the Pharmacovigilance Risk Assessment Committee (PRAC); signal rapporteur there for 70 centrally authorised medicines in 2024.
Member of	The International Coalition of Medicines Regulatory Authorities (ICMRA); the Pharmaceutical Inspection Co-operation Scheme (PIC/S), scheme member since February 1996; the Heads of Medicines Agencies (HMA) network, and the European and international device networks.

Don’t confuse it with: the EMA

HPRA

Ireland’s own authority

Licenses: medicines nationally, and inspects the sites that make them
Receives: Ireland’s reports and forwards them to EudraVigilance
Example: approves a safety letter to Irish doctors

EMA

The EU’s coordinator

Coordinates: the national authorities’ expertise across the network
Runs: EudraVigilance and the safety committee where Ireland sits
Example: gives the opinion on a medicine the HPRA assessed as rapporteur

Chapter 4

Test yourself

Myth or Truth? Pick an answer to see the explanation.

“Most suspected reaction reports the HPRA receives come from patients and doctors.”

MythTruth

MythYou got it.Not quite.

In 2024, 85.5 percent of the 7,885 reports came from marketing authorisation holders. The public and health professionals sent 7 percent each.

“A safety letter to Irish doctors needs the HPRA’s approval before it is sent.”